Swiss National Bank increased its stake in shares of Epizyme, Inc. (NASDAQ:EPZM) by 25.5% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 83,700 shares of the biopharmaceutical company’s stock after buying an additional 17,000 shares during the quarter. Swiss National Bank owned about 120,814.09% of Epizyme worth $1,594,000 at the end of the most recent reporting period.
A number of other large investors also recently modified their holdings of EPZM. Dimensional Fund Advisors LP lifted its stake in shares of Epizyme by 61.4% in the 1st quarter. Dimensional Fund Advisors LP now owns 65,194 shares of the biopharmaceutical company’s stock valued at $1,118,000 after acquiring an additional 24,807 shares during the last quarter. Schwab Charles Investment Management Inc. raised its position in Epizyme by 25.3% during the 1st quarter. Schwab Charles Investment Management Inc. now owns 161,646 shares of the biopharmaceutical company’s stock worth $2,773,000 after purchasing an additional 32,650 shares during the last quarter. State Street Corp raised its position in Epizyme by 59.6% during the 2nd quarter. State Street Corp now owns 1,764,450 shares of the biopharmaceutical company’s stock worth $26,644,000 after purchasing an additional 658,727 shares during the last quarter. Federated Investors Inc. PA raised its position in Epizyme by 477.6% during the 2nd quarter. Federated Investors Inc. PA now owns 89,505 shares of the biopharmaceutical company’s stock worth $1,352,000 after purchasing an additional 74,009 shares during the last quarter. Finally, Vanguard Group Inc. raised its position in Epizyme by 6.2% during the 2nd quarter. Vanguard Group Inc. now owns 3,419,844 shares of the biopharmaceutical company’s stock worth $51,640,000 after purchasing an additional 200,982 shares during the last quarter. 85.28% of the stock is currently owned by institutional investors and hedge funds.
In related news, insider Peter Tai-Ching Ho sold 15,000 shares of the company’s stock in a transaction on Tuesday, October 24th. The shares were sold at an average price of $16.44, for a total value of $246,600.00. Following the completion of the transaction, the insider now directly owns 23,123 shares in the company, valued at $380,142.12. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director David M. Mott bought 200,000 shares of the business’s stock in a transaction that occurred on Monday, September 18th. The stock was bought at an average price of $15.25 per share, with a total value of $3,050,000.00. Following the completion of the transaction, the director now directly owns 6,000 shares of the company’s stock, valued at approximately $91,500. The disclosure for this purchase can be found here. Insiders own 25.20% of the company’s stock.
Several research analysts have recently weighed in on the company. BidaskClub raised Epizyme from a “strong sell” rating to a “sell” rating in a research report on Tuesday. HC Wainwright reissued a “buy” rating on shares of Epizyme in a research report on Monday, August 7th. Leerink Swann restated an “outperform” rating and issued a $28.00 target price (down from $31.00) on shares of Epizyme in a research note on Wednesday, August 9th. Oppenheimer restated a “buy” rating and issued a $26.00 target price on shares of Epizyme in a research note on Tuesday, September 19th. Finally, Zacks Investment Research upgraded Epizyme from a “hold” rating to a “buy” rating and set a $20.00 price target for the company in a research note on Monday, October 16th. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and ten have assigned a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus price target of $22.67.
Shares of Epizyme, Inc. (NASDAQ EPZM) opened at $12.70 on Tuesday. Epizyme, Inc. has a 1-year low of $9.30 and a 1-year high of $20.45.
Epizyme (NASDAQ:EPZM) last issued its earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($0.63) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.65) by $0.02. analysts anticipate that Epizyme, Inc. will post -2.23 earnings per share for the current fiscal year.
TRADEMARK VIOLATION WARNING: “Swiss National Bank Has $1.59 Million Holdings in Epizyme, Inc. (NASDAQ:EPZM)” was first published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this news story on another publication, it was copied illegally and reposted in violation of United States & international copyright and trademark laws. The legal version of this news story can be viewed at https://www.dispatchtribunal.com/2017/12/05/epizyme-inc-epzm-holdings-increased-by-swiss-national-bank.html.
Epizyme, Inc is a clinical-stage biopharmaceutical company. The Company discovers, develops and plans to commercialize epigenetic therapies for cancer patients. The Company is engaged in the discovery and development of novel epigenetic therapies for cancer patients. The Company develops small molecule inhibitors of a class of enzymes known as histone methyltransferases (HMTs).
Receive News & Ratings for Epizyme Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epizyme Inc. and related companies with MarketBeat.com's FREE daily email newsletter.